Sleep Apnea and Testosterone: How OSA Suppresses Male Hormones

Obstructive sleep apnea (OSA) is the most common sleep disorder in men, affecting an estimated 10–30% of adult males. Beyond the well-known cardiovascular and metabolic consequences, OSA produces a significant hormonal effect that is frequently overlooked: suppression of testosterone production.

The mechanism is straightforward but consequential. Testosterone is primarily synthesized during sleep — particularly during slow-wave and REM sleep stages. OSA disrupts both sleep architecture and oxygenation, impairing the hormonal output that depends on undisturbed sleep.

How OSA Suppresses Testosterone

Two distinct mechanisms drive the testosterone reduction in OSA:

Sleep Architecture Disruption

The apneic events in OSA cause repeated partial awakenings that fragment sleep and reduce the proportion of deep slow-wave sleep and REM sleep. Since testosterone secretion peaks during these stages, their reduction directly reduces overnight testosterone synthesis. [^luboshitzky2002]

This is the same mechanism by which general sleep deprivation reduces testosterone — OSA essentially forces partial sleep deprivation even when men spend adequate time in bed. Men with OSA who report sleeping 7–8 hours may have hormonal profiles consistent with getting 4–5 hours of restorative sleep.

Intermittent Hypoxia

Each apneic event causes a drop in blood oxygen saturation (oxyhemoglobin desaturation). In moderate-to-severe OSA, hundreds of these desaturation events occur per night. Intermittent hypoxia has direct toxic effects on Leydig cells — the testosterone-producing cells of the testes — impairing steroidogenic function through oxidative stress and mitochondrial dysfunction. [^andersen2011]

This hypoxia-mediated mechanism is particularly important in severe OSA and explains why testosterone suppression in OSA is not solely explained by sleep fragmentation alone.

Downstream Effects

The combined effect on the HPG axis:

• Reduced LH pulse amplitude overnight (from sleep architecture disruption)
• Impaired Leydig cell responsiveness to LH (from hypoxia)
• Secondary reduction in total and free testosterone
• Often concurrent increase in estradiol (OSA is associated with obesity, which increases aromatase activity)

Magnitude of Testosterone Suppression

Population studies consistently show lower testosterone in men with OSA compared to age-matched controls without sleep disorders. [^santos2011] The reduction is dose-dependent: more severe OSA (higher apnea-hypopnea index, more severe oxygen desaturation) predicts greater testosterone suppression.

Typical findings:

• Men with severe OSA (AHI >30) show testosterone reductions of 10–25% compared to controls
• The reduction affects both total and free testosterone
• LH levels are often in the low-normal range rather than appropriately elevated, indicating suppression at the hypothalamic-pituitary level as well as the testicular level

Does Treating OSA Restore Testosterone?

CPAP (continuous positive airway pressure) is the primary treatment for moderate-to-severe OSA. Its effect on testosterone is real but partial.

Multiple studies show that CPAP treatment increases testosterone in men with OSA and low baseline testosterone. The classic study by Grunstein et al. demonstrated significant testosterone improvements after 3 months of CPAP therapy, particularly in men with the lowest pre-treatment testosterone. [^grunstein1989]

What to expect from CPAP:

• Improvement begins within weeks of consistent CPAP use
• Mean testosterone increases of 50–150 ng/dL in hypogonadal OSA patients
• Improvement is directly proportional to CPAP adherence (hours of use per night)
• Men with the lowest pre-CPAP testosterone show the greatest absolute improvement
• Not all men normalize — those with severe or long-standing hypogonadism may need additional evaluation

The testosterone response to CPAP is limited by: extent of pre-existing Leydig cell damage from chronic hypoxia, concurrent obesity (which independently suppresses testosterone through aromatase), and age-related testicular decline.

OSA, Testosterone, and Obesity: Untangling the Web

OSA, obesity, and low testosterone are deeply interconnected, with each condition worsening the others:

• Obesity deposits fat around the pharynx, worsening OSA
• Obesity increases aromatase activity, converting testosterone to estrogen
• Low testosterone promotes fat accumulation (particularly visceral fat)
• Visceral fat worsens insulin resistance, inflammation, and sleep quality
• OSA-induced testosterone suppression further promotes fat accumulation

This creates a self-reinforcing cycle that is difficult to break by addressing only one component. Men with OSA and low testosterone require comprehensive management: CPAP for OSA, weight loss, and hormonal re-evaluation after sustained treatment.

Diagnosis: Who Should Be Screened

Men presenting with low testosterone symptoms should be asked specifically about sleep quality, witnessed apneas, and snoring — which they often do not volunteer. The following presentations warrant OSA evaluation before or concurrent with low testosterone workup:

• BMI >30
• Neck circumference >17 inches
• Daytime somnolence (Epworth Sleepiness Scale >10)
• Witnessed apneas or gasping
• Hypertension (especially treatment-resistant)
• Low testosterone with normal or low-normal LH

Treating OSA before initiating testosterone replacement therapy can normalize testosterone without TRT in a meaningful proportion of men. [^wittert2014]

Sleep Apnea, Testosterone, and TRT

There is a clinical concern about testosterone replacement therapy worsening OSA. Exogenous testosterone can worsen upper airway tone and respiratory drive, and some studies show increased AHI in men starting TRT. The mechanism involves testosterone's effects on upper airway musculature and central respiratory drive. [^saaresranta2003]

For men with untreated OSA who are prescribed TRT:

• OSA should be treated first (CPAP initiated) before starting TRT
• If TRT is started in men with known OSA, OSA severity should be monitored
• Testosterone does not universally worsen OSA, but the risk is real and should be addressed

Practical Guidance

1. Screen for OSA in all men presenting with low testosterone, particularly those with obesity, hypertension, or sleep complaints
2. Home sleep testing is sufficient for diagnosing OSA in most men — a formal in-lab polysomnogram is not required
3. CPAP first: For men with OSA and low testosterone, treat OSA and reassess testosterone at 3–6 months before prescribing TRT
4. Adherence matters: CPAP must be used >4 hours per night, preferably all night, to produce meaningful hormonal benefit
5. Weight loss synergizes with CPAP for both OSA severity and testosterone improvement
6. Retest testosterone after 3–6 months of consistent CPAP use — many men improve substantially

Bottom Line

Sleep apnea directly suppresses testosterone through sleep fragmentation and intermittent hypoxia, impairing both hypothalamic-pituitary signaling and Leydig cell function. CPAP treatment partially reverses the hormonal deficit, with the greatest benefit in men with the lowest pre-treatment testosterone. OSA screening should be routine in the low testosterone workup, and OSA should be treated before testosterone replacement is initiated when both conditions coexist.